Arcus Biosciences shares rose after ARC-20 platform data showed its kidney cancer drug casdatifan outperformed competitors, with a 35-month median overall survival in late-line patients. Analysts from TD Cowen and Leerink praised the results, highlighting casdatifan's potential as a foundational RCC therapy and predicting significant stock gains.
